Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy
Public ClinicalTrials.gov record NCT02404818. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
UFPTI 1431 - HL02: Investigating Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Survivors Treated With Either Photon or Proton Radiation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate if radiation and chemotherapy treatment cause cardiac abnormalities among survivors of Hodgkin's lymphoma.
Study identification
- NCT ID
- NCT02404818
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 5 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2015
- Primary completion
- Apr 13, 2021
- Completion
- Apr 13, 2021
- Last update posted
- Jun 9, 2022
2015 – 2021
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Florida Health Proton Therapy Institute | Jacksonville | Florida | 32206 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Hodgkin's Lymphoma trials
Other public records listing Hodgkin's Lymphoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT05355051: A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma Recruiting
- NCT01788839: Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma Recruiting
- NCT01192464: EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma Active, not recruiting
- NCT01483664: Communication Skills Intervention to Promote Transition Into Survivorship Active, not recruiting
- NCT02917083: CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02404818, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2022 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02404818 live on ClinicalTrials.gov.